Official Title
Master Rollover Protocol for Continued Safety Assessment of Study Drug
Brief Summary

This study is for patients who have participated in a previous study and who continue to receive benefit to have continued access to study drug and/or treatment.

Available
Cancer

Drug: LY2503029
Administered orally.

Drug: LY3023414
Administered orally.

Eligibility Criteria

Inclusion Criteria:

- To be eligible patients must be currently receiving benefit in a concluded Lilly study for a compound that has opened an addendum in the continued access protocol.

Exclusion Criteria:

- Patients must not be concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years
Countries
United States
Locations

Fort Wayne Oncology & Hematology
Fort Wayne, Indiana, 46804

Available

Investigator: There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or 317-615-4559

Oregon Urology Institute
Springfield, Oregon, 97477

Available

Investigator: There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or 317-615-4559

Tennessee Oncology
Nashville, Tennessee, 37203

Available

Investigator: There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
Contact: 317-615-4559

Contacts

There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
1-317-615-4559

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT -5 hours, EST)
Study Director
Eli Lilly and Company

Eli Lilly and Company
NCT Number